Table 2 |
||||||
|
CK7/20 phenotype and CDX2 expression in our studied groups |
||||||
|
Colorectal AdenoCa (n = 118) |
Gastric AdenoCa (n = 59) |
Pancreatic AdenoCa (n = 32) |
||||
|
|
|
|
||||
|
CDX2+ |
CDX2- |
CDX2+ |
CDX2- |
CDX2+ |
CDX2- |
|
|
|
||||||
|
CK7-/CK20+ |
74 (62%) |
1 (1%) |
3 (5%) |
0 (0%) |
0 (0%) |
0 (0%) |
|
CK7+/CK20+ |
22 (19%) |
2 (2%) |
21 (36%) |
7 (12%) |
2 (6%) |
5 (16%) |
|
CK7+/CK20- |
2 (2%) |
0 (0%) |
8 (14%) |
11 (19%) |
3 (9%) |
21 (66%) |
|
CK7-/CK20- |
16 (14%) |
1 (1%) |
4 (7%) |
5 (9%) |
0 (0%) |
1 (3%) |
|
|
||||||
|
Bayrak et al. Diagnostic Pathology 2012 7:9 doi:10.1186/1746-1596-7-9 |
||||||
